Delivery Order SPE2DB22D3501-SPE2DB25FWR78
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $1,136.92. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $11,351.84. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award includes no set-aside designation, reflecting the contractor's established capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a ceiling value of $6,844.29. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded without a set-aside designation. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a $10,739.93 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ozempic 0.25–0.5 mg/dose pens (3 mL). This firm fixed-price delivery order is scheduled for completion by July 24, 2025, and will be performed at AmerisourceBergen's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the vendor's capability to meet federal procurement requirements through...
- The Defense Logistics Agency awarded a delivery order valued at $11,020.09 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic (0.25-0.5 mg/dose pen, 3ml) with an ultimate completion date of July 28, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,768.41 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml), with performance completion required by July 28, 2025. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $14,466.50 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3mL) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price contract, which is not set aside for any specific category, represents a small-value transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio. The award was competitively awarded and will be performed at the vendor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $10,550.33 to AmerisourceBergen Drug Corp for the supply of Ozempic (0.25-0.5 mg/dose pen, 3 mL) with a completion date of July 31, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is part of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government. The product will be delivered to the vendor's location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,266.60 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with an ultimate completion date of July 24, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to this pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a ceiling value of $18,294.14. This competitively awarded, firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWR78Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ozempic (0.25-0.5 mg/dose pen, 3ml formulation) with a ceiling value of $19,962.14. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a typical pharmaceutical procurement transaction under the company's broader federal medical supply portfolio. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. AmerisourceBergen operates as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, supplying military and veteran healthcare systems with a comprehensive range of brand-name and generic medications, vaccines, and medical supplies. The company's extensive contract awards with the Defense Logistics Agency demonstrate its established capability to fulfill federal pharmaceutical requirements across multiple therapeutic domains, supporting defense health operations globally.